FDA Instability Is Changing Biotech Investment—What Investors Are Saying

FDA instability is reshaping biotech investment decisions in real time. Investors are recalibrating risk, pulling back, and even shifting capital abroad.In this episode of the Making Medicine Podcast, John Stanford is joined by Rachel Sher of Manatt Health to unpack new original research conducted with investors across the biotech ecosystem. The goal was simple: move beyond speculation and understand whether recent leadership changes, staffing cuts, and policy uncertainty at FDA are actually shaping investor behavior.What emerged is a clear signal. Across venture capital, public equity, private equity, and industry investors, the vast majority said recent changes at FDA have altered how they think about risk, capital allocation, and the attractiveness of U.S.-based drug development.This conversation walks through the four major themes that surfaced in the research: growing concern about regulatory instability, reduced appetite for certain product categories like gene therapy and vaccines, increasing attention to China and other international markets, and broader concern that instability across agencies like NIH and FDA could weaken the long-term innovation pipeline.At the center of it all is one core issue: regulatory predictability. When investors lose confidence in consistency, policy clarity, and institutional knowledge, the consequences extend far beyond individual companies. They affect portfolios, research priorities, and where innovation happens next.This episode also highlights something important. Even with all these concerns, investors still want to back innovation in the United States. The question is whether policymakers and regulators can restore the stability and trust that made the U.S. the global leader in biotech in the first place.Watch for a grounded conversation on what investors are really saying, what it means for the biotech ecosystem, and why FDA predictability matters more than ever.Check out the full reporthttps://www.incubatecoalition.org/post/one-pager-complete-report-regulatory-instability-at-fda-is-reshaping-biotech-investmentJoin the Conversation ⬇️Do you think FDA instability is already changing the future of biotech investment? Are investors right to look abroad when U.S. regulatory signals become less predictable? What matters more right now: speed, stability, or scientific consistency?Drop your thoughts in the comments below 👇If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:  https://x.com/MakingMedPodhttps://www.instagram.com/makingmedicinepod/https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTime Stamps00:00 Intro & Disclaimer00:16  Investors Say FDA Changes Are Impacting Decisions03:22 How We Surveyed Investors (Research Design)07:27 Theme 1: FDA Instability & Investor Uncertainty10:22 Investors Repricing Risk in Biotech12:05  “Chaos Is the Only Thing” – Investor Quote13:00  Theme 2: Pullback from Gene Therapy, Vaccines, Oncology14:28  Theme 3: Capital Shifting Abroad (China & Competition)17:02 Theme 4: NIH Cuts & Long-Term Innovation Risk 25:24 Key Takeaway: Regulatory Predictability Drives InvestmentDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor. #Biotech #FDA #BiotechInvesting #HealthcarePolicy #DrugDevelopment